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Not an Alternative
Keratinocyte carcinomas 
(KCs) are typically treated 
with a wait-and-cut approach. 
Systemic retinoids have 
shown promise for reducing 
the risk of new basal cell and 
squamous cell carcinomas in 
high-risk patients, albeit with 
adverse effects. Weinstock 
and colleagues therefore 
performed a randomized 
controlled trial to examine the 
effectiveness of topical tretinoin 
in reducing the risk of KCs in a 
high-risk population of 1,131 
participants (the VATTC Trial). 
This retinoid was ineffective 
for chemoprevention of these 
carcinomas and precursor 
actinic keratosis. Despite the 
common use of this agent to 
improve photoaging, novel 
reagents for chemoprevention 
are needed. See page 1583
More Than One a Day
Both retinoids and carotenoids 
have shown antimelanoma 
effects in laboratory studies; 
however, epidemiological 
studies have reported 
conflicting results. In a 
prospective cohort study 
of 69,635 individuals (the 
Vitamins and Lifestyle (VITAL) 
Study), Asgari and colleagues 
found that dietary and 
supplemental vitamin A intake 
in the form of supplemental 
retinol was associated with a 
reduction in melanoma risk, 
and this reduction was more 
pronounced in women. No 
association between carotenoid 
intake and melanoma risk 
was detected. Therefore, 
vitamin A supplementation as 
a chemopreventive agent for 
melanoma should be further 
examined. See page 1573
Getting Personal
Epidermal palmoplantar kera-
toderma (EPPK), which is 
caused by autosomal-domi-
nant mutations in the human 
keratin K9 gene (KRT9), is a 
prime candidate for the use 
of siRNA-based treatments 
for personalized inhibition of 
gene expression, particularly because 90% of EPPK cases result from missense muta-
tions in one of three hotspot codons. Leslie Pedrioli and colleagues developed and 
tested a two-pronged RNAi-based therapeutic package for EPPK in cultured cells and 
in a mouse footpad model. This identification of potent and highly specific generic and 
allele-specific inhibitors of the KRT9 gene in EPPK serves as the preclinical basis for 
development of a clinically applicable personalized siRNA therapy for this keratinizing 
disorder. See page 1627
A Gentle Approach
Geriatric skin, which is highly 
susceptible to nonmelano-
ma skin cancers, exhibits an 
ineffective UVB response. 
Although harsh dermabrasion 
therapies have been shown to 
reverse the characteristics of 
UV exposure in geriatric skin, 
Spandau and colleagues dem-
onstrated that the corrective ability of fractionated laser resurfacing (FLR), which induces 
a gentler wounding response without the morbidity of dermabrasion, is far superior to 
that of dermabrasion. Treatment of geriatric skin with FLR decreased the number of senes-
cent fibroblasts, increased collagen production and IGF-1 expression, and restored the 
appropriate UV response in skin. These results offer promise for the development of a 
prophylactic treatment for at-risk geriatric patients. See page 1591
Regeneration Revisit
Although transplantation of autologous 
skin grafts is the gold standard for chronic 
wound treatment, problems with morbidity, 
graft failure, and limited availability of tis-
sue abound. Danner and colleagues found 
that human sweat gland–derived stem 
cells (SGSCs) seeded in collagen scaffolds, 
which have been used successfully in tis-
sue engineering, improved vascularization 
during dermal regeneration and secreted 
bioactive molecules involved in angiogenesis, immune function, and tissue remodeling. 
These easily accessible SGSCs were expanded ex vivo to yield a therapeutic cell number. 
Thus, combined use of SGSCs and cellular scaffolds may be useful for clinical dermal 
regeneration. See page 1707
Journal of Investigative Dermatology (2012) 132, 1526. doi:10.1038/jid.2012.157
